Product Highlight - Esmya

16 Dec 2016
Product Highlight - Esmya
ESMYA – Ulipristal acetate 5 mg tab – Zuellig Pharma

ESMYA is a 1st in class oral therapy approved in Malaysia to treat moderate to severe symptomatic uterine fibroids
  • 1 week to stop menstrual bleeding (median time) and bleeding was controlled in 90% of patients2
  • 1st oral therapy proven to shrink uterine fibroids’ size effectively2
  • 1 tablet once a day, convenient dosing regimen1
References:
1. Donnez J,et al.N Engl J Med,2012;366(5):409-20
2. Donnez J,et al.N Engl J Med,2012;366(5):421-32
3. Esmya currently approved package insert 02/02/2015 (Based on EU SPC 19/12/2013)

Further information is available in section 10c, New In This Issue and mims.com.
Full prescribing information is available upon request.

Related MIMS Drugs

Editor's Recommendations